Dark Blue Therapeutics Ltd is a biotechnology company based in Oxford, UK, founded in 2020 as a spinout from the University of Oxford. The company specializes in precision oncology, developing first-in-class small-molecule therapies that target novel cancer vulnerabilities, including protein degraders.
Its lead candidate, DBT-3757, is a targeted protein degrader of MLLT1/3 proteins, advancing through IND-enabling studies for the treatment of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). The preclinical program demonstrates promising anti-cancer activity and potential as a single-agent therapy.
In January 2026, Dark Blue Therapeutics was acquired by Amgen in a deal valued at up to $840 million, integrating its pipeline into Amgen's oncology research efforts to address unmet needs in difficult-to-treat cancers like AML.
